Nexium Capsules Clinical Experience Investigation
Launched by ASTRAZENECA · Sep 14, 2011
Trial Information
Current as of April 24, 2025
Completed
Keywords
ClinConnect Summary
Nexium capsules Clinical Experience Investigation
Gender
ALL
Eligibility criteria
- • Inclusion Criteria: - Patients treated with Nexium for the first time due to gastric ulcer, duodenal ulcer, anastomotic ulcer, reflux oesophagitis, non-erosive reflux disease, Zollinger-Ellison syndrome. Exclusion Criteria: - None
Trial Officials
Shigeru Yoshida, MD
Study Director
AstraZeneca
About Astrazeneca
AstraZeneca is a global biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative medicines across various therapeutic areas, including oncology, cardiovascular, respiratory, and autoimmune diseases. With a strong commitment to scientific research and patient-centric solutions, AstraZeneca leverages cutting-edge technology and a robust pipeline to address unmet medical needs. The company collaborates with healthcare professionals, academic institutions, and other organizations to advance clinical trials and deliver transformative therapies, aiming to improve health outcomes and enhance the quality of life for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Chiba, , Japan
Fukuoka, , Japan
Kumamoto, , Japan
Niigata, , Japan
Oita, , Japan
Osaka, , Japan
Saitama, , Japan
Tokyo, , Japan
Gifu, , Japan
Nagasaki, , Japan
Okayama, , Japan
Yamagata, , Japan
Hiroshima, , Japan
Kyoto, , Japan
Toyama, , Japan
Kagoshima, , Japan
Tochigi, , Japan
Kochi, , Japan
Fukushima, , Japan
Miyazaki, , Japan
Shizuoka, , Japan
Yamaguchi, , Japan
Gunma, , Japan
Hyogo, , Japan
Ibaraki, , Japan
Kanagawa, , Japan
Nagano, , Japan
Wakayama, , Japan
Akita, , Japan
Tottori, , Japan
Ehime, , Japan
Hokkaido, , Japan
Aichi, , Japan
Nara, , Japan
Tokushima, , Japan
Aomori, , Japan
Kagawa, , Japan
Okinawa, , Japan
Saga, , Japan
Fukui, , Japan
Iwate, , Japan
Mie, , Japan
Miyagi, , Japan
Shiga, , Japan
Shimane, , Japan
Ishikawa, , Japan
Yamanashi, , Japan
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials
Related Blog Entries
View all
